Estimated Plasma Volume in Patients With Acute Heart Failure
NCT ID: NCT07085793
Last Updated: 2025-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2500 participants
OBSERVATIONAL
2019-01-01
2023-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The objectif is to assess the prognostic value of admission ePVS, calculated using Duarte and Hakim formulas, for short- and long-term mortality and/or readmission in patients hospitalized for AHF.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Heart Failure in Elderly Patients Admitted to the Emergency Department with Acute Dyspnea: a Multimarker Approach Prognostic Study
NCT06692439
Prospective Validation of the Emergency Heart Failure Mortality Risk Grade (EHMRG) Score in Patients With Acute Heart Failure in the Emergency Department
NCT05710302
Evaluate the Predictive Impact of the EHMRG
NCT05632263
Heart Risk 6 Scale in Emergency Department Acute Heart Failure Patients
NCT06664073
Acute Heart Failure Study in Patients Admitted to Emergency Department for Dyspnea
NCT02835963
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
ePVS at admission was calculated as follows:
* Duarte ePVS= 100-ht(%) /Hb(g/dl).
* Hakim ePVS = \[(actual plasma volume-ideal plasma volume)/ideal plasma volume\] × 100 Actual plasma volume: (1-hematocrit) × (a+b×body weight in kg). Ideal plasma volume = c×body weight in kg. (males: a = 1530, b = 41.0, c = 39; females; a = 864, b = 47.9, c = 40)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
1
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Exclusion Criteria
* end-stage or severe renal failure with creatinine clearance \< 15 ml/min
* hemodialysis.
* refusal to consent
* Pregnant or breast feeding women.
* Alteration of consciousness GCS \< 15
* Critically ill patients needing immediate mechanical hemodynamic of ventilatory support.
* Inability to follow instructions or comply with follow-up procedures.
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Monastir
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pr. Semir Nouira
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Semir Nouira, Pr
Role: PRINCIPAL_INVESTIGATOR
University of Monastir
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Emergency Department
Monastir, , Tunisia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Estimated plasma volume- ePVS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.